Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O6VZ
|
|||
| Former ID |
DNCL003482
|
|||
| Drug Name |
GDC-0980/RG7422
|
|||
| Synonyms |
Apitolisib; 1032754-93-0; GDC-0980; GDC0980; RG7422; (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one; UNII-1C854K1MIJ; GDC-0980 (RG7422); Apitolisib (GDC-0980, RG7422); 1C854K1MIJ; CHEMBL1922094; RG-7422; (2s)-1-(4-{[2-(2-Aminopyrimidin-5-Yl)-7-Methyl-4-(Morpholin-4-Yl)thieno[3,2-D]pyrimidin-6-Yl]methyl}piperazin-1-Yl)-2-Hydroxypropan-1-One; J-502360; C23H30N8O3S
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [2] | ||
| Company |
Genentech; Roche
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H30N8O3S
|
|||
| Canonical SMILES |
CC1=C(SC2=C1N=C(N=C2N3CCOCC3)C4=CN=C(N=C4)N)CN5CCN(CC5)C(=O)C(C)O
|
|||
| InChI |
1S/C23H30N8O3S/c1-14-17(13-29-3-5-31(6-4-29)22(33)15(2)32)35-19-18(14)27-20(16-11-25-23(24)26-12-16)28-21(19)30-7-9-34-10-8-30/h11-12,15,32H,3-10,13H2,1-2H3,(H2,24,25,26)/t15-/m0/s1
|
|||
| InChIKey |
YOVVNQKCSKSHKT-HNNXBMFYSA-N
|
|||
| CAS Number |
CAS 1032754-93-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
58088126, 85071230, 126497218, 136340124, 136349560, 136367691, 136920331, 136936437, 136962228, 141811291, 143499857, 144116008, 152233031, 152255050, 152255768, 152258485, 160647320, 160657174, 162011357, 162038118, 162202638, 163643094, 164045108, 174525857, 184816736, 189622848, 198974042, 223377949, 224209864, 226784456, 242772564, 249565579, 252109872, 252160446, 252451804, 252543421
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Roche. | |||
| REF 2 | Clinical pipeline report, company report or official report of Genentech (2011). | |||
| REF 3 | GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther. 2011 Dec;10(12):2426-36. | |||
| REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.